Endothelial cell growth factor
CA 2005600 A1 · Owner: Ishikawa, Fuyuki · Inventors: Takaku, Fumimaro; Ishikawa, Fuyuki; Hellman, Ulf
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family. PD-ECGF appears to be the only endothelial cell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e. the ability to stimulate the formation of new blood vessels and chemotactic activity in vitro. The, present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past the, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 14, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 14, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 14, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.